WebOct 25, 2024 · October, 25, 2024 Data Presented at ACG Shows Guardant Health’s Blood-Based Test Accurately Detects Early-Stage Colorectal Cancer This study indicates Guardant Health’s blood test could provide meaningful clinical performance in an average risk screening population WebApr 11, 2024 · REDWOOD CITY, Calif.-- (BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new data …
Guardant Health announces positive results from pivotal ECLIPSE …
WebGuardant Health has advanced our technology to include screening for early CRC detection 2,9. We are dedicated to supporting patients with cancer across the continuum of care. … WebAt Guardant Health, each day starts and ends with putting the patient first. We are a team of diverse, passionate, and curious individuals, motivated to transform cancer care for patients at all stages of the disease. And we’re looking for bright minds to join us. VIEW OPEN POSITIONS Our mission Our mission is to conquer cancer with data. mc well services
Health literacy and colorectal cancer screening - GuardantHealth
WebNov 11, 2024 · The primary objective of the study is to evaluate the sensitivity and specificity of a blood-based GuardantLUNAR-2 test to detect high frequency cancer in screen-relevant populations. The SHIELD study will recruit patients in separate cancer-risk cohorts with specified pathways for cancer screening. WebApr 11, 2024 · PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that it will present data from 14 studies highlighting advances in precision oncology and cancer screening at the 2024 American Association for Cancer Research (AACR) Annual Meeting, April 14-19 in … WebMay 9, 2024 · NEW YORK – Having officially launched its Shield colorectal cancer screening assay last week as a laboratory-developed test, Guardant Health has become the first of several companies expected to compete in a … life of mahatma gandhi essay